Over Half of Oncology Resources Are Allocated to Innovative, High-Cost Therapies

The increase in oncological pathologies and the arrival of new innovative therapies has meant that 60% of oncology resources are allocated to high-cost treatments. This highlights the urgency of efficient management that guarantees an adequate use of resources and equity in access to treatments.

That was highlighted at the meeting organised by the Spanish Society of Health Directors (Sedisa) and the ECO Foundation, with the collaboration of the Daiichi Sankyo alliance with AstraZeneca.

The event aimed to analyse the challenges of modern oncology and propose measures to improve the quality of management in this field

Jesús Sanz Villorejo, vice-president of the Sedisa Foundation, pointed out that “it is crucial to analyse the situation and the challenges to achieve excellence in the approach to oncology”. Among the main challenges addressed, he stressed the need to optimise the resources allocated to oncological treatments, which represent a great burden for the health system due to their high cost.

“Reaching consensus on proposals to improve management and create projects that respond to oncology needs and define the most relevant challenges from different perspectives and professional profiles is of utmost importance. For this reason, we are holding this event, which aims to propose measures to improve the situation and define the steps to carry out oncological management,” said the vice president of Sedisa.

Dr. Jesús García-Foncillas, president of the ECO Foundation, emphasized the importance of taking into account the oncology patients’ perspective. “It is not only important to do things well, but also to take into account the quality perceived by our patients,” said García-Foncillas, who stressed the importance of integrating the patients’ perception into the planning of oncological management.

The meeting was attended by health managers, oncologists, patients and representatives of regional health services. Together, they addressed the need to create projects that respond to the needs of the system, such as improving equity in access to new therapies. In this regard, the importance of investing in prevention and in management models that ensure the sustainability of the system was stressed.

Finally, the Sedisa Observatory of Value-Based Management was presented . It seeks to define the bases for the implementation of this management model in the health system. The proposed roadmap proposes measures to improve the quality of life of patients, ensure the efficiency of treatments and guarantee that resources are used appropriately in a context of increasing population ageing and greater demand for oncological services.

__

(Featured image by Ousa Chea via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in iSanidad. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us